##gff-version 3								
##gvf-version 1.10								
##species NCBI_Taxonomy_URI=http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049								
#seqid	#source	#type	#start	#end	#score	#strand	#phase	#attributes
MN908947.3	.	snp	174	174	.	+	.	ID=ID_0;Name=c.G-92T;chrom_region=5' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G-92T;aa_name=;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	241	241	.	+	.	ID=ID_1;Name=c.C-25T;chrom_region=5' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C-25T;aa_name=;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	1059	1059	.	+	.	ID=ID_2;Name=p.T265I;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C794T;aa_name=p.T265I;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	2692	2692	.	+	.	ID=ID_3;Name=p.T809T;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp2;mat_pep_desc=produced by both pp1a and pp1ab;mat_pep_acc=YP_009725298.1;ro=145;ao=673;dp=818;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A2427T;aa_name=p.T809T;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.8227383863080685;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	3037	3037	.	+	.	ID=ID_4;Name=p.F924F;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2772T;aa_name=p.F924F;vcf_gene=orf1ab;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	5100	5100	.	+	.	ID=ID_5;Name=p.S1612L;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=664;ao=154;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C4835T;aa_name=p.S1612L;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.1882640586797066;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	5230	5230	.	+	.	ID=ID_6;Name=p.K1655N;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp3;mat_pep_desc=former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725299.1;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G4965T;aa_name=p.K1655N;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	10323	10323	.	+	.	ID=ID_7;Name=p.K3353R;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=3C-like proteinase;mat_pep_desc=nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab;mat_pep_acc=YP_009725301.1;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A10058G;aa_name=p.K3353R;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_8;Name=p.S3675del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='3676del', 'F3677del';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp,snp	14408	14410	.	+	.	ID=ID_9;Name=p.P4715H;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=448,370;dp=818;sample_size=818;Reference_seq=C;Variant_seq=A,T;nt_name=c.C14144A;aa_name=p.P4715H;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_8;Name=p.3676del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', 'F3677del';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_8;Name=p.F3677del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', '3676del';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	11287	11287	.	+	.	ID=ID_8;Name=p.3676del;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=nsp6;mat_pep_desc=nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab;mat_pep_acc=YP_009725302.1;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=GTCTGGTTTT;Variant_seq=G;nt_name=c.11023_11031delTCTGGTTTT;aa_name=p.S3675_F3677del;vcf_gene=orf1ab;mutation_type=;viral_lineage=B.1.351;multi_aa_name=S3675_F3677del;multiaa_comb_mutation='S3675del', 'F3677del';alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp,snp	14408	14410	.	+	.	ID=ID_9;Name=p.P4715H;chrom_region=ORF1ab;ps_filter=;ps_exc=;mat_pep_id=RNA-dependent RNA polymerase;mat_pep_desc=nsp12, NiRAN and RdRp, produced by pp1ab only;mat_pep_acc=YP_009725307.1;ro=0;ao=448,370;dp=818;sample_size=818;Reference_seq=C;Variant_seq=A,T;nt_name=c.C14144A;aa_name=p.P4715H;vcf_gene=orf1ab;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	"ID=ID_10;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.01.14.426475;citation=McCallum et al. (2021);comb_mutation=;function_description=Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_10;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_11;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_10;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggetsing that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_13;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	"ID=ID_10;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_10;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_11;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	"ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_12;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_14;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1;citation=Cai et al. (2021);comb_mutation='D80A', 'L242del';function_description=The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion... which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this region.;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21614	21614	.	+	.	ID=ID_11;Name=p.L18F;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=327;ao=490;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C52T;aa_name=p.L18F;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5997552019583844;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_15;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation='D215G', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_16;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_17;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_18;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Abolishes neutralizing activity of N-terminal-domain-directed mAb 4-19.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_19;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_18;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_17;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_16;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_13;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	"ID=ID_18;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_18;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_19;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_16;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_16;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_16;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_17;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_16;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	"ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_15;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='D215G', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_20;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_18;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://www.medrxiv.org/content/10.1101/2021.02.11.21251585v1;citation=Redd et al. (2021);comb_mutation=;function_description=One individual of 30 in the study, with HLA supertype HLA*A24:02, had a linear epitope that overlaps this variant of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_12;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_14;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1;citation=Cai et al. (2021);comb_mutation='L18F', 'L242del';function_description=The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion... which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this region.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_18;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated that there is no free energy change (ddG) for this variant (i.e. same stability as wild type) ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_15;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation='D215G', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_15;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation='D215G', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	21801	21801	.	+	.	ID=ID_19;Name=p.D80A;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=C;nt_name=c.A239C;aa_name=p.D80A;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_15;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation='D80A', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_21;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1;citation=Borges et al. (2021);comb_mutation=;function_description=In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_16;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_17;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_22;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_21;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_17;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_16;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_13;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	"ID=ID_21;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_21;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_22;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_16;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_16;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_16;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_17;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_16;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	"ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_15;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='D80A', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_20;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_12;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_21;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.98 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_15;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation='D80A', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_15;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation='D80A', 'K417N', 'A701V', 'N501Y', 'E484K';function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22206	22206	.	+	.	ID=ID_22;Name=p.D215G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A644G;aa_name=p.D215G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L241del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L242del', 'A243del';alternate_frequency=0.9875;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_15;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_17;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	"ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation='E484K', 'N501Y';function_description=The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd = 145.1nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_28;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'D614G';function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_29;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'D614G';function_description=Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=Teyssou et al. (2021);comb_mutation='E484K', 'N501Y';function_description=The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=Roquebert et al. (2021);comb_mutation='E484K', 'N501Y';function_description=B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_30;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='E484K';function_description=Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_31;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='N501Y';function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_17;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'E484K';function_description=~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_13;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='E484K', 'N501Y';function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P=0.0361.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	"ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	"ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_17;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'E484K';function_description=In post-vaccination sera from individuals who received one (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype  lentivirus vs D614G was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_28;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'D614G';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_29;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'D614G';function_description=This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	"ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_15;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V';function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation='E484K', 'N501Y';function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=Wu et al. (2021);comb_mutation='E484K', 'N501Y';function_description=In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_15;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_15;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation=;function_description=Ablates binding of Spike N terminal domain targeting monoclonal antibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  501Y.V2 (""South African"") lineage background variant R246I to disrupt paratope binding. [PG: del extent simplified to accomodate minor position realignments];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 2-17, and 4-19 (independent of S:p.R246I).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  deletion does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_35;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_36;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1;citation=Cai et al. (2021);comb_mutation='L18F', 'D80A';function_description=The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion... which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this region.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_37;Name=p.A243del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'L242del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.A243del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'L242del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.A243del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'L242del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation=;function_description=Ablates binding of Spike N terminal domain targeting monoclonal antibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  501Y.V2 (""South African"") lineage background variant R246I to disrupt paratope binding. [PG: del extent simplified to accomodate minor position realignments];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 2-17, and 4-19 (independent of S:p.R246I).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  deletion does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abf6950;citation=McCarthy et al. (2021);comb_mutation=;function_description=Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_35;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_23;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_32;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	"ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_34;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_33;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	del	22280	22280	.	+	.	ID=ID_36;Name=p.L242del;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=1;ao=711;dp=720;sample_size=818;Reference_seq=ACTTTACTTG;Variant_seq=A;nt_name=c.719_727delCTTTACTTG;aa_name=p.L241_A243del;vcf_gene=S;mutation_type=;viral_lineage=B.1.351;multi_aa_name=L241_A243del;multiaa_comb_mutation='L241del', 'A243del';alternate_frequency=0.9875;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1;citation=Cai et al. (2021);comb_mutation='L18F', 'D80A';function_description=The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion... which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this region.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_15;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_17;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	"ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation='E484K', 'N501Y';function_description=The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd = 145.1nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_28;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'D614G';function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_29;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'D614G';function_description=Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=Teyssou et al. (2021);comb_mutation='E484K', 'N501Y';function_description=The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=Roquebert et al. (2021);comb_mutation='E484K', 'N501Y';function_description=B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_30;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='E484K';function_description=Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_31;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='N501Y';function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_17;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'E484K';function_description=~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_13;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='E484K', 'N501Y';function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P=0.0361.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	"ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	"ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_17;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_16;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'E484K';function_description=In post-vaccination sera from individuals who received one (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype  lentivirus vs D614G was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_28;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'D614G';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_29;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'D614G';function_description=This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_26;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'N501Y', 'D614G';function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	"ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='E484K', 'N501Y';function_description=Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_15;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='D80A', 'D215G', 'E484K', 'N501Y', 'A701V';function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation='E484K', 'N501Y';function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_25;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=Wu et al. (2021);comb_mutation='E484K', 'N501Y';function_description=In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV016;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_20;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_12;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=gene expression increase;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, Spike gene expression increased 0.1 fold;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_24;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_15;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_15;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation='D80A', 'D215G', 'A701V', 'N501Y', 'E484K';function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	22813	22813	.	+	.	ID=ID_27;Name=p.K417N;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=814;dp=814;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G1251T;aa_name=p.K417N;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_15;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'N501Y';function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_16;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_17;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation=;function_description=Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation='K417N', 'N501Y';function_description=Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1;citation=Li et al. (2021);comb_mutation=;function_description=Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	"ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation='K417N', 'N501Y';function_description=Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='K417N', 'N501Y';function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_39;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='N501Y';function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2;citation=Gaebler et al. (2021);comb_mutation=;function_description=Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2020);comb_mutation=;function_description=Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://science.sciencemag.org/content/371/6531/823;citation=Rappazzo et al. (2021);comb_mutation=;function_description=Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_40;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y', 'D614G';function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_41;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_39;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation='N501Y';function_description=In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation='K417N', 'N501Y';function_description=The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd = 38.5nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected variants in an in vitro evolution experiment for ACE2 binding.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.06 fold;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_40;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y', 'D614G';function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_40;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y', 'D614G';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_41;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_40;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'D614G';function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'D614G';function_description=Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferriera et al (2021);comb_mutation=;function_description=This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=Teyssou et al. (2021);comb_mutation='K417N', 'N501Y';function_description=The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=Roquebert et al. (2021);comb_mutation='K417N', 'N501Y';function_description=B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_30;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='K417N';function_description=Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_39;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='N501Y';function_description=Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1;citation=Schmidt et al. (2021);comb_mutation=;function_description=Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_41;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_17;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_16;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'K417N';function_description=~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_13;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation=;function_description=Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	"ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1;citation=Zhou et al. (2021);comb_mutation=;function_description=Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation='K417N', 'N501Y';function_description=Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='K417N', 'N501Y';function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_39;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='N501Y';function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2;citation=Liu et al. (2021);comb_mutation=;function_description=Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41586-021-03398-2;citation=Wang et al. (2021);comb_mutation=;function_description=The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	"ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	"ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2020.12.28.424451;citation=Andreano et al. (2020);comb_mutation=;function_description=This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_41;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_16;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_41;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D614G';function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_16;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_16;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_17;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_16;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1084/jem.20202756;citation=Solfrosi et al. (2021);comb_mutation=;function_description=Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation=;function_description=E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S2666-5247(21;citation=Jangra et al. (2021);comb_mutation=;function_description=Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'K417N';function_description=In post-vaccination sera from individuals who received one (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype  lentivirus vs D614G was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_41;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_40;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y', 'D614G';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_29;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'D614G';function_description=This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_26;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'N501Y', 'D614G';function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1;citation=Ferreira et al. (2021);comb_mutation=;function_description=Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	"ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='K417N', 'N501Y';function_description=Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_15;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'A701V';function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation='K417N', 'N501Y';function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_25;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=Wu et al. (2021);comb_mutation='K417N', 'N501Y';function_description=In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_39;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation='N501Y';function_description=The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P=0.8774)];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_39;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01270-4;citation=Xie et al. (2021);comb_mutation='N501Y';function_description=In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=http://dx.doi.org/10.1126/science.abd0831;citation=Baum et al. (2020);comb_mutation=;function_description=Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf;citation=Weisblum et al. (2020);comb_mutation=;function_description=Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin=ppub;citation=Barnes et al. (2020);comb_mutation=;function_description=The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://doi.org/10.1016/j.chom.2020.11.007;citation=Greaney et al. (2020);comb_mutation=;function_description=Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1;citation=Starr et al. (2021);comb_mutation=;function_description=Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_20;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_12;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_38;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_15;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'N501Y';function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_15;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'N501Y';function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23012	23012	.	+	.	ID=ID_41;Name=p.E484K;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=810;dp=810;sample_size=818;Reference_seq=G;Variant_seq=A;nt_name=c.G1450A;aa_name=p.E484K;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.nejm.org/doi/full/10.1056/NEJMc2031364;citation=Choi et al. (2020);comb_mutation=;function_description=Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=T cell evasion;source=https://science.sciencemag.org/content/early/2021/04/29/science.abh1282;citation=Reynolds et al. (2021);comb_mutation=;function_description=Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p = 0.0286).  Furthermore, the T cell response to the spike N501Y mutation common to all three of the current VOC was ablated.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_15;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'E484K';function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=homoplasy;source=https://www.mdpi.com/2076-0817/10/2/184/htm;citation=Flores-Alanis et al. (2021);comb_mutation=;function_description=Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_16;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_17;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1;citation=Sun et al. (2021);comb_mutation='K417N', 'E484K';function_description=Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1101/2021.04.26.441517;citation=Klegerman et al. (2021);comb_mutation=;function_description=Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'E484K', 'D614G';function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1;citation=Wibmer et al. (2021);comb_mutation='K417N', 'E484K';function_description=Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='K417N', 'E484K';function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='E484K';function_description=Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1;citation=Haynes et al. (2021);comb_mutation=;function_description=Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation=;function_description=Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1;citation=Rees-Spear et al. (2021);comb_mutation=;function_description=Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='E484K', 'D614G';function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation=;function_description=The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation='E484K';function_description=In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1;citation=Barton et al. (2021);comb_mutation='K417N', 'E484K';function_description=The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=~4-fold increase in binding affinity vs wild type.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1;citation=Santos and Passos (2021);comb_mutation=;function_description=In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd = 45.2nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation=;function_description=The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1;citation=Laffeber et al. (2021);comb_mutation=;function_description=RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41586-021-03412-7;citation=Collier et al. (2021);comb_mutation=;function_description=This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.08.012;citation=Starr et al. (2020);comb_mutation=;function_description=Experimentally, ACE2 binding affinity increased 0.24 fold;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.06.425392;citation=Zahradnik et al. (2021);comb_mutation=;function_description=Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd = 455 pM vs 1600pM);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1;citation=Liu et al. (2021);comb_mutation=;function_description=Reported 10-fold increase in ACE2 binding vs wildtype (Kd = 0.566nM vs 5.768 nM);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2;citation=Tian et al. (2021);comb_mutation=;function_description=Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd = 13.1nM vs 56.9nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2;citation=Zhu et al. (2021);comb_mutation=;function_description=N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1;citation=Ramanathan et al. (2021);comb_mutation=;function_description=Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1;citation=Gamez et al. (2021);comb_mutation=;function_description=The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='E484K', 'D614G';function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='D614G';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='E484K', 'D614G';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_28;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'D614G';function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'D614G';function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'K417N', 'D614G';function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1;citation=Motozono et al. (2021);comb_mutation=;function_description=Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'E484K', 'D614G';function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1;citation=Teyssou et al. (2021);comb_mutation='K417N', 'E484K';function_description=The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2;citation=Roquebert et al. (2021);comb_mutation='K417N', 'E484K';function_description=B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1;citation=Liu et al. (2021);comb_mutation=;function_description=This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation=;function_description=COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='E484K';function_description=Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_31;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=pharmaceutical effectiveness;source=https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1;citation=Engelhart et al. (2021);comb_mutation='K417N';function_description=COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_17;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_16;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'E484K';function_description=~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1;citation=Tang et al. (2021);comb_mutation=;function_description=As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_13;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'E484K', 'D614G';function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='K417N', 'E484K', 'D614G';function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2;citation=Shen et al. (2021);comb_mutation=;function_description=Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1;citation=Vogel et al. (2021);comb_mutation='K417N', 'E484K';function_description=Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='K417N', 'E484K';function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01294-w ;citation=Chen et al. (2021);comb_mutation='E484K';function_description=In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf;citation=Cele et al. (2021);comb_mutation=;function_description=The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1101/2021.01.18.427166;citation=Wibmer et al. (2021);comb_mutation=;function_description=27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation='K417N', 'E484K', 'D614G';function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation='K417N', 'E484K', 'D614G';function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_16;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_16;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_16;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_17;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_16;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1;citation=Edara et al. (2021);comb_mutation=;function_description=1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='K417N', 'E484K', 'D614G';function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'E484K';function_description=In post-vaccination sera from individuals who received one (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) of the BNT162b2 Pfizer vaccine, an average 6.8x reduction in neutralization efficacy of this B.1.351 key variants pseudotype  lentivirus vs D614G was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='D614G';function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_28;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'D614G';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_40;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'D614G';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_26;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'E484K', 'D614G';function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	"ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='K417N', 'E484K';function_description=Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation=;function_description=Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1101%2F2021.01.19.21249592;citation=Rathnasinghe et al. (2021);comb_mutation=;function_description=Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2;citation=Jacobson et al. (2021);comb_mutation=;function_description=The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_15;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'A701V';function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation='K417N', 'E484K';function_description=In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_25;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1;citation=Wu et al. (2021);comb_mutation='K417N', 'E484K';function_description=In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01294-w;citation=Chen et al. (2021);comb_mutation='E484K';function_description=The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P=0.8774)];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_39;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01270-4;citation=Xie et al. (2021);comb_mutation='E484K';function_description=In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=monoclonal antibody serial passage escape;source=https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2;citation=Wang et al. (2021);comb_mutation=;function_description=In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=environmental condition stability;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_20;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_12;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_42;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_15;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'E484K';function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_15;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'A701V', 'E484K';function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23063	23063	.	+	.	ID=ID_43;Name=p.N501Y;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=807;dp=807;sample_size=818;Reference_seq=A;Variant_seq=T;nt_name=c.A1501T;aa_name=p.N501Y;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=immunosuppression variant emergence;source=https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1;citation=Landis et al. (2021);comb_mutation=;function_description=Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_16;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_17;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'E484K', 'N501Y';function_description=Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_40;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=syncytium formation;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='E484K', 'N501Y';function_description=~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_11;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L18F';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_19;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D80A';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_22;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D215G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_27;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='K417N';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_41;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='A701V';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://doi.org/10.1016/j.cell.2020.07.012;citation=Li et al. (2020);comb_mutation=;function_description=In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_40;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='E484K', 'N501Y';function_description=~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation=;function_description=No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='N501Y';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_40;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.3390%2Fv13040633;citation=Kim et al. (2021);comb_mutation='E484K', 'N501Y';function_description=More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_41;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_27;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N';function_description=~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_28;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'N501Y';function_description=~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_40;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'N501Y';function_description=~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'K417N';function_description=Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'K417N', 'N501Y';function_description=~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'E484K', 'N501Y';function_description=The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1;citation=Barrett et al. (2021);comb_mutation=;function_description=Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry);heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et l. (2020);comb_mutation=;function_description=We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.nature.com/articles/s41467-021-21118-2;citation=Ozono et al. (2020);comb_mutation=;function_description=Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://doi.org/10.7554/elife.65365;citation=Daniloski et al. (2021);comb_mutation=;function_description=The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation=;function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=viral load;source=https://www.nature.com/articles/s41586-020-2895-3;citation=Plante et al. (2020);comb_mutation=;function_description=Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_41;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='E484K';function_description=Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_17;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_16;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_13;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1;citation=Hu et al. (2021);comb_mutation='K417N', 'E484K', 'N501Y';function_description=Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='K417N', 'E484K', 'N501Y';function_description=Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf;citation=Pearson et al. (2021);comb_mutation='K417N', 'E484K', 'N501Y';function_description=Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=transmissibility;source=https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1;citation=Roquebert et al. (2021);comb_mutation='K417N', 'E484K', 'N501Y';function_description=36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_11;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L18F';function_description=1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_19;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D80A';function_description=2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_22;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D215G';function_description=2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_27;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='K417N';function_description=2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_41;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='A701V';function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_16;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1;citation=Abe et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y';function_description=In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_41;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='E484K';function_description=Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_16;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1;citation=Tada et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y';function_description=Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_16;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1;citation=Pegu et al (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y';function_description=Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_17;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_16;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='K417N', 'E484K', 'N501Y';function_description=In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='N501Y';function_description=This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_41;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_27;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N';function_description=This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_28;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'N501Y';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_40;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='E484K', 'N501Y';function_description=This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_29;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'E484K';function_description=This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_26;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation='K417N', 'E484K', 'N501Y';function_description=This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n = 5) or two doses (9–11 days post-second dose:  n = 10) neutralization efficiency vs D614G (using lentivirus pseudotype).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.1016%2Fj.chom.2021.03.008;citation=Kuzmina et al. (2021);comb_mutation=;function_description=Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation=;function_description=Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_20;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_12;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.nature.com/articles/s41467-020-19808-4;citation=Zhang et al. (2020);comb_mutation=;function_description=Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/;citation=Yurkovetskiy et al. (2020);comb_mutation=;function_description=CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	"ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2;citation=Weissman et al. (2020);comb_mutation=;function_description=Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_44;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_43;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='N501Y';function_description=1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_11;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='L18F';function_description=1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_19;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D80A';function_description=1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_22;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D215G';function_description=1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_27;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='K417N';function_description=1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_41;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='E484K';function_description=1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23403	23403	.	+	.	ID=ID_45;Name=p.D614G;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=A;Variant_seq=G;nt_name=c.A1841G;aa_name=p.D614G;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='A701V';function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_15;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=symptom prevalence;source=https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1;citation=Munster et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'E484K';function_description=Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_17;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=antibody epitope effects;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_45;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=ACE2 receptor binding affinity;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_46;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=trafficking;source=https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1;citation=Tada et al. (2021);comb_mutation=;function_description=Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=tissue specific neutralization;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=outcome hazard ratio;source=https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348;citation=Funk et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_17;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_13;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma escape;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_45;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=convalescent plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_17;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1126/science.abg9175;citation=Stamatatos et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/nejmoa2103055;citation=Shinde et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1;citation=Ikegame et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1172/jci149335;citation=Woldemeskel et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1056/NEJMoa2102214;citation=Madhi et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1;citation=Tarke et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=PBMCs of Pfizer/BioNTech BNT162b2 (n=8) 12-15 days post booster and Moderna mRNA-1273 COVID-19 vaccines (n=11) 13-30 days post-booster  were stimulated with the Spike 15-mer peptide pools (w/ 10 residue overlaps), and showed for B.1.351 a CD4+ cell count decrease (29%, p=0.00063)   as well as CD8+ (33%, p=0.0016) by Activation Induced Marker (AIM) assay (cellular immunity measurement).  No signficant change in IF-gamma or IL-5 spot forming cell counts were observed.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nature.com/articles/s41591-021-01318-5;citation=Planas et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/S0140-6736(20;citation=Voysey et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.];heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1;citation=Gallagher et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1;citation=Choi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.03.013;citation=Garcia-Beltran et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://doi.org/10.1016/j.cell.2021.02.037;citation=Zhou et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Sera from healthcare workers (n = 25) 4–17 days following the second dose of Pfizer vaccine, administered 3 weeks after  the first dose, showed geometric mean titers for B.1.351  7.6-fold lower than for an early Victoria sample (p < 0.0001). For the AstraZeneca vaccine, samples (n = 25) were obtained 14 or 28 days following the second vaccine dose, with a dosing  interval of 8–14 weeks, geometric mean B.1.351 titers were 9-fold lower than for Victoria (p < 0.0001).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf;citation=Novavax (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=;citation=;comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1;citation=Madhi et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	"ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1;citation=Bates et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20).;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_15;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1;citation=Alenquer et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'E484K', 'N501Y';function_description=Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccine neutralization efficacy;source=https://www.nejm.org/doi/full/10.1056/NEJMc2102017;citation=Liu et al. (2021);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_20;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=humoral response durability;source=https://doi.org/10.1093/cid/ciab308;citation=Betton et al. (2020);comb_mutation='D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_12;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=CD8 plus T cell response;source=https://doi.org/10.21203/rs.3.rs-226857/v1;citation=Skelly et al. (2021);comb_mutation='L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G';function_description=Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_46;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=virion structure;source=https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1;citation=Spratt et al. (2021);comb_mutation=;function_description=Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type) ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_15;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1;citation=Yinda et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'E484K';function_description=Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  ;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_15;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=reinfection;source=https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423;citation=Staub et al. (2021);comb_mutation='D80A', 'D215G', 'K417N', 'N501Y', 'E484K';function_description=4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	23664	23664	.	+	.	ID=ID_45;Name=p.A701V;chrom_region=S;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C2102T;aa_name=p.A701V;vcf_gene=S;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=vaccinee plasma binding;source=https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1;citation=Gong et al. (2021);comb_mutation='D614G';function_description=1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	25563	25563	.	+	.	ID=ID_47;Name=p.Q57H;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G171T;aa_name=p.Q57H;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	25614	25614	.	+	.	ID=ID_48;Name=p.S74S;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=549;ao=269;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C222T;aa_name=p.S74S;vcf_gene=ORF3a;mutation_type=SILENT;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.32885085574572126;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	25784	25784	.	+	.	ID=ID_49;Name=p.W131L;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=368;ao=444;dp=812;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G392T;aa_name=p.W131L;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5467980295566502;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	25904	25904	.	+	.	ID=ID_50;Name=p.S171L;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=808;dp=808;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C512T;aa_name=p.S171L;vcf_gene=ORF3a;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	26152	26152	.	+	.	ID=ID_51;Name=p.G254X;chrom_region=ORF3a;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=370;ao=448;dp=818;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G760T;aa_name=p.G254X;vcf_gene=ORF3a;mutation_type=NONSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.5476772616136919;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	26456	26456	.	+	.	ID=ID_52;Name=p.P71L;chrom_region=E;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=818;dp=818;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C212T;aa_name=p.P71L;vcf_gene=E;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	27870	27870	.	+	.	ID=ID_53;Name=c.G-24T;chrom_region=intergenic;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=706;ao=110;dp=816;sample_size=818;Reference_seq=G;Variant_seq=T;nt_name=c.G-24T;aa_name=;vcf_gene=ORF8;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13480392156862744;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	mnp,snp	28253	28257	.	+	.	ID=ID_54;Name=p.I121L;chrom_region=ORF8;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=114,695;dp=809;sample_size=818;Reference_seq=CA;Variant_seq=TC,TA;nt_name=c.CA360_361TC;aa_name=p.I121L;vcf_gene=ORF8;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	28887	28887	.	+	.	ID=ID_55;Name=p.T205I;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=0;ao=817;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C614T;aa_name=p.T205I;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=1.0;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=True;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
MN908947.3	.	snp	29358	29358	.	+	.	"ID=ID_56;Name=p.T362I;chrom_region=N;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=703;ao=114;dp=817;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C1085T;aa_name=p.T362I;vcf_gene=N;mutation_type=MISSENSE;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.13953488372093023;function_category=T cell evasion;source=https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1;citation=de Silva et al. (2021);comb_mutation=;function_description=Variant causes complete loss of T cell line responsiveness to A*03:01/A*11:01-restricted CD8+ N epitope  KTFPPTEPK 361-369(2,8,10,20), which otherwise is ""consistently dominant and of high magnitude"".;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;"
MN908947.3	.	snp	29754	29754	.	+	.	ID=ID_57;Name=c.C29754T;chrom_region=Stem-loop,3' UTR;ps_filter=;ps_exc=;mat_pep_id=;mat_pep_desc=;mat_pep_acc=;ro=554;ao=232;dp=786;sample_size=818;Reference_seq=C;Variant_seq=T;nt_name=c.C*4370T;aa_name=;vcf_gene=intergenic;mutation_type=;viral_lineage=B.1.351;multi_aa_name=;multiaa_comb_mutation=;alternate_frequency=0.2951653944020356;function_category=;source=;citation=;comb_mutation=;function_description=;heterozygosity=False;clade_defining=False;who_variant=Beta;status=VOC;voi_designation_date=;voc_designation_date=18-Dec-2020;vum_designation_date=;
